FosB is a divalent-metal-dependent thiol-S-transferase implicated in fosfomycin resistance among many pathogenic Gram-positive bacteria. In the present paper, we describe detailed kinetic studies of FosB from Staphylococcus aureus (SaFosB) that confirm that bacillithiol (BSH) is its preferred physiological thiol substrate. SaFosB is the first to be characterized among a new class of enzyme (bacillithiol-S-transferases), which, unlike glutathione transferases, are distributed among many low-G + C Gram-positive bacteria that use BSH instead of glutathione as their major low-molecular-mass thiol. The K m values for BSH and fosfomycin are 4.2 and 17.8 mM respectively. Substrate specificity assays revealed that the thiol and amino groups of BSH are essential for activity, whereas malate is important for SaFosB recognition and catalytic efficiency. Metal activity assays indicated that Mn 2 + and Mg 2 + are likely to be the relevant cofactors under physiological conditions. The serine analogue of BSH (BOH) is an effective competitive inhibitor of SaFosB with respect to BSH, but uncompetitive with respect to fosfomycin. Coupled with NMR characterization of the reaction product (BSfosfomycin), this demonstrates that the SaFosB-catalysed reaction pathway involves a compulsory ordered binding mechanism with fosfomycin binding first followed by BSH which then attacks the more sterically hindered C-1 carbon of the fosfomycin epoxide. Disruption of BSH biosynthesis in S. aureus increases sensitivity to fosfomycin. Together, these results indicate that SaFosB is a divalent-metal-dependent bacillithiol-S-transferase that confers fosfomycin resistance on S. aureus.
INTRODUCTION
The antibiotic fosfomycin [(1R,2S)-epoxypropylphosphonic acid] possesses broad-spectrum activity against both Gram-positive and Gram-negative bacteria [1] . It is a covalent inhibitor of MurA, a key enzyme that mediates the first obligate step in peptidoglycan biosynthesis [2] . Covalent inhibition of MurA results from nucleophilic attack by an active-site cysteine thiol at the less hindered C-2 position of the fosfomycin epoxide [3] . To date, three different types of fosfomycin-resistance enzymes have been identified (FosA, FosB and FosX), which can inactivate fosfomycin by ring opening of the epoxide motif [4] . FosX is a metal-dependent hydrolase found in Mesorhizobium loti and Listeria monocytogenes, which catalyses the hydrolysis of the epoxide [5, 6] . FosA has been characterized as a manganese-dependent glutathione transferase which catalyses glutathione (GSH)-dependent ring opening at the more sterically hindered C-1 position of the fosfomycin epoxide to form an inactive GS-fosfomycin conjugate ( Figure 1A ) [7] [8] [9] [10] . Both plasmid-and chromosome-encoded fosA genes have been identified in various Gram-negative bacteria [9, 11, 12] .
FosB is a thiol-S-transferase related to FosA. The fosfomycinresistance gene fosB has been identified in the chromosomes and on plasmids in many low-G + C Gram-positive bacteria that do not produce GSH [4, [13] [14] [15] [16] . Until recently, the potential identity of the native thiol substrate for FosB had long been elusive. Previous kinetic studies of FosB from Bacillus subtilis (BsFosB) revealed negligible activity towards GSH and no apparent activity for CoA [16] . Cysteine also proved to be a poor thiol substrate with a very high K m of 35 mM, which is approximately 200-fold greater than its intracellular concentration [17] .
In 2009, bacillithiol (BSH) ( Figure 1B ) was identified as a unique low-molecular-mass thiol among numerous low-G + C Gram-positive bacteria (Firmicutes) that do not produce GSH. These include several pathogens, such as Staphylococcus aureus (bacterial sepsis), Staphylococcus saprophyticus (urinary tract infection), Bacillus cereus (food poisoning) and Bacillus anthracis (livestock pathogen and biowarfare agent), as well as B. subtilis (soil bacterium) and Deinococcus radiodurans (extremophile) [18] . All of these bacteria also harbour a fosB gene. BSH-deficient mutants of B. subtilis [19] and B. anthracis [20] exhibit increased sensitivity to fosfomycin. In B. subtilis, this increased fosfomycin sensitivity was comparable with that observed in the fosB mutant and in a double mutant for both fosB and BSH biosynthesis, which suggested that FosB utilizes BSH as its native thiol substrate [19] . A total chemical synthesis of BSH [21] recently provided sufficient material for preliminary activity assays, which, at fixed thiol substrate concentrations (1 mM), demonstrated S. aureus FosB (SaFosB) to be significantly more active with BSH than cysteine. This supported further the notion of FosB being a bacillithiol-S-transferase.
S. aureus
Newman and MRSA wild-type strains, as well as the BSH-deficient MRSA strains, NE1728 (bshA mutant), NE1596 (bshB mutant) and NE230 (bshC mutant), were grown in TSB (trypticase soy broth) with 0, 1, 2.5, 5, 7.5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 100, 120, 140 or 160 μg · ml − 1 fosfomycin. Growth was monitored at D 600 and the experiment was performed in triplicate. LB (Luria-Bertani) agar plates supplemented with 0-20 mg · ml − 1 fosfomycin were used to determine the MIC (minimum inhibitory concentration) values for Escherichia coli transformed with pET151:FosB, as well as the B. subtilis CU1065 wild-type and B. subtilis CU1065 bshA mutant.
Thiol quantification in S. aureus and the effect of fosfomycin on thiol content S. aureus Newman was grown in 100 ml of TSB in two sets of triplicate cultures. When the D 600 reached 0.7, one set of triplicate cultures was treated with a sub-lethal concentration of fosfomycin (5 μg · ml − 1 ) and the remaining set was left untreated. The D 600 was monitored and samples corresponding to approximately 5 mg of residual dry weight of cells were harvested from each culture at various times for analysis of thiol content. Cell pellets were frozen at − 20
• C until derivatization with mBBr (monobromobimane) and analysis by reverse-phase HPLC as described previously [18] . BSmB (bacillithiol-bimane) and CySmB (cysteinyl-bimane) were eluted at 8 and 10 min respectively, and were quantified by comparison with RSmB (methylbimane derivative of thiol) standards of known concentration.
SaFosB cloning, overexpression and purification
FosB was amplified from S. aureus strain ATCC25923 DNA with the primers SaFosBF2 (5 -CACCATGTTAAAATCTATTAAT-C-3 ) and SaFosBR2 (5 -TTATTTGTAAAATGTCATATGTGG-TTT-3 ), and cloned into pET151 (Invitrogen) with an additional stop codon and native promoter to prevent fusion with the His 6 tag. The expression plasmid was transformed into BL21 Star TM (DE3) E. coli cells. The culture was grown to a D 600 of 1.5 in Terrific broth at room temperature (22 • C) before induction with 25 μM IPTG (isopropyl β-D-thiogalactopyranoside) for 20 h. Cells were harvested and stored at − 80
• C. The frozen cell pellet was thawed in lysis buffer (20 mM potassium phosphate, pH 6.8, 10 % glycerol and 60 mM NaCl) and was disrupted by sonication. The supernatant was applied to a 5 ml SP Sepharose HiTrap ion-exchange column (GE Healthcare) equilibrated with lysis buffer, which was subsequently washed with lysis buffer supplemented with 40 mM NaCl. Proteins were eluted with 200 mM NaCl and were pooled and concentrated by centrifugation in an Amicon spin column (Millipore), before applying to a 5 ml hydroxyapatite column equilibrated with 60 mM potassium phosphate (pH 6.8) and 10 % glycerol. The column was washed with 80 mM potassium phosphate, and proteins were eluted at 300 mM potassium phosphate. Purified SaFosB was treated with the Na + -form of 100 mesh Chelex (3 g, Bio-Rad Laboratories) and 5 mM EDTA overnight. EDTA was then removed with a PD-10 desalting column (GE Healthcare) equilibrated with 10 % glycerol. FosB was then concentrated to 280 μM in an Amicon spin column (Supplementary Figure S2 at http://www.biochemj.org/bj/451/bj4510069add.htm).
Synthesis of BSH analogues
The chemical syntheses of MeO-GlcNCys [O-methylglucosamine cysteine (O-methylbacillithiol)], BnO-GlcNCys [Obenzylglucosamine cysteine (O-benzylbacillithiol)] and BOH (serine analogue of BSH) are described in the Supplementary Online Data and Supplementary Scheme S1 at http://www.biochemj. org/bj/451/bj4510069add.htm.
SaFosB thiol specificity assays by thiol consumption
Assays for BSH, cysteine, N-acetylcysteine, GSH, homocysteine, γ -Glu-Cys, CoA, MeO-GlcNCys and BnO-GlcNCys consisted of 50 mM Hepes (pH 7.0), 1 mM MgCl 2 , 5 mM fosfomycin and 10 μM SaFosB and mixtures were incubated at 22
• C for 5 min. Reactions were then initiated with the addition of 2 mM thiol, and aliquots were taken at various time points and mixed immediately with 10 mM DTNB [5,5 -dithiobis-(2-nitrobenzoic acid)] [23] in 50 mM sodium phosphate buffer (pH 7.5) with 20 mM KCl and 1 mM MgCl 2 . The absorbance of each reaction was measured at 412 nm to calculate the consumption of thiol using the molar absorption coefficient of 14 150 M − 1 [24] . Control reactions performed without enzyme determined the background (nonenzymatic) oxidation of each thiol.
HPLC-based SaFosB assays monitoring RS-fosfomycin formation
In general, SaFosB activity assays consisted of Chelex-treated Hepes (pH 7.0), fosfomycin, SaFosB and M 2 + (divalent metal ions) at various concentrations (see the Figure legends for individual assay details). Assay mixtures were equilibrated at 22
• C for at least 5 min before initiating reactions by the addition of the thiol substrate. After 1 min, the reactions were stopped by heating at 85
• C for 10 min and then cooled to room temperature before derivatization for 1 min in sodium borate buffer (pH 8.8) with at least 4 molar excess of AQC with respect to the total amine content of the assay. After AQC derivatization, samples were diluted with 70 mM sodium acetate and 6.25 mM triethylamine, adjusted to pH 5.05 with phosphoric acid (solvent A) for analysis by HPLC. When product formation was below the limit of detection, AQC-labelled samples were first dried in vacuo and resuspended in a minimal volume of solvent A. Control experiments showed that all enzyme reactions were linear for at least 5 min.
HPLC analysis of AQC-labelled samples
RS-fosfomycin samples were analysed on a HiChrom ACE C 18 , 4.6 mm diameter×250 mm length, 5 μM particle size and 100 Å (1 Å = 0.1 nm) pore size column equilibrated to 37
• C with 90 % solvent A and 10 % solvent B (80 %, v/v, acetonitrile). Samples were eluted with a flow rate of 1.5 ml · min − 1 using the following gradient of solvent B: 0-4 min, 10 %; 4-8 min, 10-12 %; 8-10 min, 12-15 %; 10-13 min, 15-40 %; 13-15 min, 40-100 %. A Jasco fluorescence detector was used to analyse the samples, with excitation at 250 nm and emission at 395 nm. RS-fosfomycin was quantified using a standard curve of AQC-derivatized RSfosfomycin standards of known concentration. HPLC retention times of the AQC-derivatized RS-fosfomycin conjugates were: BS-fosfomycin (bacillithiol-fosfomycin) (4.8 min), cysteinefosfomycin (6.9 min), MeO-GlcNCys-fosfomycin (9.6 min) and BnO-GlcNCys-fosfomycin (12.7 min).
SaFosB substrate saturation assays
For the saturated substrate kinetics of SaFosB with BSH, a 7×7 matrix of initial rate reactions were constructed with various concentrations of BSH (0.1-2 mM) and fosfomycin (1-25 mM). Reaction mixtures consisted of 50 mM Hepes (pH 7.0), 5 mM MnCl 2 and 50 nM SaFosB. Assays were performed as detailed above and initial reaction rates were determined using analytical HPLC. The results for various fosfomycin concentrations were fitted by non-linear regression to the velocity equation for a rapid equilibrium ternary complex system using GraFit version 5.
Inhibition assays
Duplicate assay mixtures consisted of 150 mM Hepes (pH 7.0), 5 mM MnCl 2 , 50 nM SaFosB and 0, 1, 3 or 8 mM BOH inhibitor. In the reactions with various BSH concentrations (0.125-6 mM), the fosfomycin concentration was fixed at 15 mM. For the reactions where fosfomycin concentration varied (2-75 mM), the BSH concentration was fixed at 2.5 mM. Reactions were carried out and analysed as described above.
Enzymatic synthesis of RS-fosfomycin standards
BS-fosfomycin was prepared by incubating BSH (6.8 mg) in 10 ml of 20 mM ammonium formate buffer (pH 7.0) containing MnCl 2 (0.1 mM), fosfomycin (1.3 mM) and SaFosB (1 μM) at room temperature. Thiol consumption was monitored over time (by titrating aliquots with DTNB), until the reaction was complete after 2 h. The reaction mixture was freeze-dried (to remove excess ammonium formate) and then resuspended in 2 ml of water, adjusted to pH 3 with 0.1 % formic acid. The solution was applied to a cation-exchange column (Isolute-SCX2 SPE, 0.5 g), eluted with water (10 ml) and dried. The resultant residue was resuspended in water (5 ml) and adjusted to pH 8.0 with 2 % (v/v) aqueous ammonia, then purified further by anion-exchange chromatography using DEAE-cellulose (1 g, AX, fibrous fast flow, Sigma) packed in an SPE cartridge. The product was eluted with a 10-200 mM stepwise gradient of ammonium bicarbonate using 12 ml portions at 10-20 mM increments. Fractions containing the product (which eluted at 100-120 mM) were identified by spotting on a TLC plate and staining with ninhydrin or charring with 10 % (v/v) ethanolic sulfuric acid.
Preparations of cysteine-fosfomycin, MeO-GlcNCysfosfomycin and BnO-GlcNCys-fosfomycin were carried out in a similar manner, using 9.6 mg of cysteine, 7.1 mg of MeOGlcNCys or 7.4 mg of BnO-GlcNCys with an equimolar amount of fosfomycin in 40 mM ammonium formate (pH 7.0) with 0.5 mM MnCl 2 and 2 μM FosB. The reactions were allowed to proceed for 16 h at room temperature. Purification was performed as above. For BnO-GlcNCys-fosfomycin, an addition final purification step was required on an Isolute C 18 (5 g) column by gradient elution using 0.1 % formic acid in water and acetonitrile. 31 P-NMR was used to confirm product purity and excess ammonium bicarbonate was removed by repeated freeze-drying. For use as HPLC standards, RS-fosfomycin concentrations were determined by quantitative 1 H-NMR [25] . The final isolated yields of the products were: BS-fosfomycin, 3.5 mg, 44 % yield; cysteine-fosfomycin, 6.6 mg, 32 % yield; MeO-GlcNCysfosfomycin, 1.2 mg, 11 % yield; and BnO-GlcNCys-fosfomycin, 4.1 mg, 39 % yield.
RESULTS AND DISCUSSION

Fosfomycin resistance in S. aureus wild-type and BSH-deficient mutants
The involvement of BSH in fosfomycin resistance in S. aureus was established by testing the fosfomycin-sensitivity of wildtype and mutant strains deficient in each of the BSH biosynthetic genes (bshA-C). The MIC for the wild-type S. aureus MRSA strain, grown in TSB, was 80 μg · ml − 1 , whereas the MICs for its BSH-deficient mutants were 10-20 μg · ml − 1 . To ensure that this resistance was not restricted to MRSA strains, the MIC of S. aureus Newman was also tested and was shown to be the same as the MRSA wild-type (80 μg · ml − 1 ). These results are consistent with previous reports in B. subtilis [19] and B. anthracis [20] , although the effect is less pronounced for S. aureus. We observed a 60-fold lower MIC in the B. subtilis BSH-deficient mutant compared with the wild-type, whereas there is only a 4-8-fold change in S. aureus (Table 1) . This difference could be due to variations in the intracellular concentrations and BSHdependent activities of FosB and/or differences in fosfomycinuptake rates and potency against MurA in the different bacteria.
In B. anthracis, the bshB mutant is less sensitive to fosfomycin than the bshA mutant [20] . This is due to the presence of a separate bacillithiol-S-conjugate amidase (Bca) that is able to complement for the GlcNAc-malate N-deacetylase activity of BshB in BSH biosynthesis. S. aureus, however, does not encode a separate Bca enzyme and therefore the bshB mutant is equally as sensitive to fosfomycin as the bshA mutant ( Table 1) . The increased sensitivity of the BSH-deficient mutants to fosfomycin implies that co-administration of a BSH biosynthesis inhibitor with fosfomycin could enhance the efficacy of fosfomycin against BSH-utilizing Gram-positive pathogens. The high incidence of MurA [26] and GlpT [12] mutations (also conferring resistance to fosfomycin) in clinical settings, however, may counter any efficacy of this therapeutic strategy. Interestingly, although E. coli does not produce BSH, an E. coli strain transformed with the SaFosB overexpression vector showed a 400-fold increase in fosfomycin resistance (Table 1) . These data are consistent with similar observations of the BsFosB overexpression plasmid in E. coli [16] . Whereas cysteine is a much less efficient FosB substrate than BSH (see below), presumably the high levels of overexpressed SaForB in this E. coli strain are sufficient for it to effectively utilize cysteine in the absence of BSH to confer fosfomycin resistance.
Effect of fosfomycin on intracellular BSH and cysteine content in S. aureus
The changes in intracellular BSH and cysteine levels were compared when S. aureus was challenged with sub-lethal (5 μg · ml − 1 ) quantities of fosfomycin ( Figure 2 ). The D 600 of the cultures was slightly affected by fosfomycin, reaching 2.0 in the treated cultures compared with 2.9 in the control. Whereas there was no immediate lag in growth after fosfomycin treatment, BSH levels decreased slightly; presumably due to conjugation of BSH to fosfomycin for detoxification. After 1 h, there was no difference between BSH levels in fosfomycin-treated and control cultures. However after 4 h, as the cells entered the stationary phase, intracellular BSH levels increased 2-fold in the treated cultures, whereas there was a 3-fold decrease in BSH content in the control. This difference may be due to the increased transcription of BSH biosynthetic genes, which could be up-regulated to compensate for the consumption of BSH in fosfomycin detoxification. The effect of fosfomycin on BSH, but not on cysteine, levels indicates a more prominent role for BSH in response to S. aureus being challenged by fosfomycin.
Assay development
Previous assays for FosA and FosB utilized an assay buffer containing either Hepes [4, 10, 27] or sodium borate [9] at pH 8.0. As some thiols have the tendency to oxidize to their disulfides under aerobic conditions at alkaline pH, we tested the stability of cysteine and BSH in Hepes buffers of pH 7.0-8.0. No oxidation of cysteine was detected over 1 h under any of the pH conditions tested. BSH was more prone to oxidation with 10 % (at pH 7.5) and 20 % (at pH 8.0) of the thiol being oxidized after 1 h, compared with only 3 % oxidation at pH 7.0 (Supplementary Figure S1 at http://www.biochemj.org/bj/ 451/bj4510069add.htm). No significant difference in SaFosB activity was observed between pH 6.0 and pH 8.0, in contrast with FosA, which has an activity optimum at pH 8.0 [7] . Therefore, to minimize the potential for thiol oxidation, all of the SaFosB activity assays in the present study were carried out at pH 7.0. In addition, the thiol substrate was added last to initiate the 1 min reactions, before quenching and derivatization with AQC for HPLC analysis.
Divalent metal ion specificity
The divalent metal cation in FosA and FosB plays an essential role in bidentate co-ordination to the phosphonate motif of fosfomycin, as well as stabilizing the negative charge generated on the epoxide oxygen during the transition state [28, 29] . FosA has previously been demonstrated to be a Mn 2 + -dependent enzyme [9] . However, previous studies on the activation of BsFosB with cysteine reported that the cysteine-S-transferase activity with 0.5 mM Mg 2 + was almost 10-fold greater than with 0.5 mM Mn 2 + [16] , with an activation constant for Mg 2 + of 200 μM that is well below cellular Mg 2 + concentrations. This supported the likelihood of Mg 2 + being the native metal ion cofactor in vivo. In the present study, similar assays with SaFosB showed no difference in the cysteine-S-transferase activity with 0.5 mM concentrations of Mn 2 + or Mg 2 + ( Figure 3A ). In the presence Figure S3 at http://www.biochemj.org/bj/451/ bj4510069add.htm), which is consistent with previous reports on FosB activity for cysteine [4, 16] . Metal activation studies identified increased bacillithiol-S-transferase activity for SaFosB in the presence of increasing concentrations of Zn 2 + , Ni
and Mn 2 + ( Figure 3B ). These metal activation curves followed sigmoidal kinetics with K act values of 1.2, 3.1 and 3.7 mM for Zn 2 + , Ni 2 + and Mn 2 + respectively. The rates of reaction with 10 mM Mn 2 + or Ni 2 + were 25-and 60-fold greater than that for equivalent concentrations of Mg 2 + . The high K act values for SaFosB suggest that the metal cofactor is not tightly bound to the enzyme.
The cellular concentrations of free Ni 2 + are well below the activation constant observed for this metal cation [30] . This suggests that Ni 2 + is unlikely to be a physiologically relevant metal that contributes to SaFosB activity in vivo and it was therefore not pursued further. [30] , although the amount of free cytosolic Zn 2 + is suggested to be maintained in the femtomolar range by the zinc-uptake regulator Zur [31] . As BSH levels in S. aureus are thought to be ∼ 200 μM [18] , it would appear that, under these conditions, Zn 2 + is also unlikely to be the physiological metal for in vivo activation of SaFosB.
In contrast, the BSH concentration did not notably inhibit the activation of SaFosB by Mn 2 + , and the sigmoidal nature of the activation curves did not become prominent until at least 1.5 mM Mn 2 + , which is much greater than cellular Mn 2 + concentrations ( Figure 4B ). Interestingly, the activity for SaFosB at physiological Mn 2 + concentrations (∼ 10 μM) [30] is only approximately 5-fold greater than in the presence of physiological Mg 2 + concentrations (∼ 10 mM) [30] (Figure 3B would be maintained at low-micromolar levels [33] by the Mn 2 + -dependent transcriptional regulator MntR [34, 35] .
Detailed substrate saturation kinetics for BSH and fosfomycin
Detailed substrate kinetic assays were performed for BSH in the presence of 5 mM Mn 2 + to determine the kinetic constants under saturating substrate conditions. The reciprocal plots obtained from these data at various fosfomycin concentrations gave a family of converging lines consistent with a rapid equilibrium ternary substrate complex mechanism ( Figure 6A ). It was initially surprising to observe that the saturation substrate kinetics extrapolated a high K m value for BSH of 4.2 mM (Table 2) relative to the cytosolic concentrations of BSH in S. aureus (∼ 200 μM) [18] . A high K m value of 17.8 mM was also obtained for fosfomycin, which is similar to that reported for the E. coli FosA (9.4 mM) [7] . Closer analysis revealed how K m (app) values for both BSH (Table 2 ) and fosfomycin (Table 3) decrease with decreasing co-substrate concentration, although there is no significant change in the overall catalytic efficiency (k cat /K m ) ( Figure 7) . These results suggest elements of negative co-operativity between the binding of these two substrates to the SaFosB homodimer. Others have previously alluded that the K m of fosfomycin with FosA can also increase in the presence of increasing thiol substrate concentrations [10] , so such cooperative substrate interactions appear to be present in both FosA and FosB enzymes alike.
Although (Table 2) . We propose that turnover rates derived in the presence of both 10 μM Mn 2 + and 10 mM Mg 2 + are more representative of SaFosB's intracellular activity. It is unlikely that intracellular fosfomycin concentrations would ever reach saturating levels, so the K m (app) for BSH should be much closer to its intracellular concentration under physiological conditions presented when cells are challenged with fosfomycin. Although previous substrate kinetics for FosA reported relatively high K m values for GSH (6-11 mM) [7, 10] , these concentrations are comparable with intracellular GSH levels. The relatively high saturating K m value for BSH, compared with its cellular concentrations, and its lower k cat value (compared with that of FosA) indicate that SaFosB is a less efficient S-transferase for fosfomycin detoxification than the GSH-dependent FosA.
No S-transferase activity was observed between BSH and the epoxide-containing antibiotic cerulenin in the presence of a large excess of SaFosB (2 μM). This suggests that FosB does not have broad-range activity against epoxide-containing electrophiles in general.
Substrate-binding order
The serine analogue of BSH (BOH) was synthesized (Supplementary Scheme S1) to establish whether the SaFosB reaction pathway proceeds via a random or compulsory ordered substrate-binding mechanism ( Figure 6 ). When BOH (1 mM) and fosfomycin (25 mM) were incubated with high concentrations of SaFosB (1 μM), no BO-fosfomycin product formation was detected. This indicates that BOH is not a substrate for SaFosB and that the thiol motif of BSH is essential for FosB-catalysed ring opening of the fosfomycin epoxide.
Inhibition assays showed BOH to be a competitive inhibitor of BSH with a K i of 3.9 mM compared with a K m (app) of 1.6 mM for BSH ( Figure 6B ), demonstrating that BOH is an effective substrate mimic of BSH. The effective inhibition of FosB by BOH also reveals that the thiol group has little impact on substrate recognition compared with the malate moiety (see below).
BOH also proved to be an uncompetitive inhibitor with respect to fosfomycin ( Figure 6C ). Taken together, these data indicate that the FosB-catalysed reaction proceeds via a rapid equilibrium compulsory ordered binding mechanism with fosfomycin binding first followed by BSH, and where the binding of either substrate increases the K m (app) for the second substrate (Figure 7) . High BSH concentrations also appear to inhibit SaFosB in a metalindependent manner, but only in the presence of low fosfomycin concentrations (Supplementary Figure S4 at http://www. biochemj.org/bj/451/bj4510069add.htm). Under these conditions, if BSH binds first, the active site will be blocked thereby preventing fosfomycin binding and subsequent catalysis. This inhibition is overcome when fosfomycin concentrations are high enough to outcompete BSH, enabling fosfomycin to bind to FosB first. A fosfomycin-bound structure of FosB from B. anthracis strain Ames has recently been deposited in the PDB (PDB code 4IR0). This structure shows how the enzyme-bound fosfomycin is buried at the bottom of a narrow binding pocket which would clearly be inaccessible if BSH were to bind first ( Figure 8A , and Supplementary Figure S6 at http://www.biochemj.org/bj/451/bj4510069add.htm). 
Regiochemistry of the BS-fosfomycin product
To confirm the regiochemistry of the FosB-catalysed reaction with BSH, SaFosB was used for the enzymatic synthesis of milligram quantities of BS-fosfomycin. The regiochemistry of the BSfosfomycin product resulting from nucleophilic attack of BSH at the C-1 carbon of fosfomycin ( Figure 1A ) was confirmed by two-dimensional NMR spectroscopy, with a three-bond HMBC (heteronuclear multiple bond correlation) between the 13 C resonance of C-1 on the fosfomycin moiety and the methylene protons (H-3 ) on the cysteine side chain (Figure 9) . A similar correlation was also observed between cysteine C-3 and the fosfomycin H-1 nuclei. The same HMBCs were also observed with the enzymatically synthesized cysteine-, MeO-GlcNCysand BnO-GlcNCys-fosfomycin adducts (Supplementary Figure  S8 at http://www.biochemj.org/bj/451/bj4510069add.htm). This regioselectivity has been reported previously for FosB-mediated fosfomycin conjugation with cysteine [16] , and for the analogous FosA-catalysed reaction with GSH [10] , confirming the conserved mechanism among this family of thiol-S-transferases.
Thiol substrate specificity
Substrate kinetics for BSH, and a number of other potential thiol substrates, were measured in the presence of fosfomycin (50 mM) and physiological metal concentrations (10 μM Mn 2 + and 10 mM Mg 2 + ) [30] ( Table 2) . None of GSH, CoA, N-acetylcysteine or homocysteine was turned over by SaFosB; neither was γ -Glu-Cys (a biosynthetic precursor of GSH, which serves as a GSH surrogate in some lactic acid bacteria) [36] . In addition, no fosfomycin hydrolase activity (with water) was observed ( Table 2 and Supplementary Figure S7 at http://www.biochemj. org/bj/451/bj4510069add.htm). Cysteine was the only other biologically relevant thiol that was recognized, with a K m (app) value of 157 mM (Table 2) , which is approximately three orders of magnitude greater than its intracellular concentration. Interestingly, the k cat values for BSH and cysteine are comparable. Therefore the 30-fold higher substrate specificity (k cat /K m ) for BSH is attributed to substrate-binding affinity. In the presence of cellular thiol concentrations, BSH will clearly be much more efficient than cysteine as a SaFosB substrate in vivo. Substituting the malate motif on BSH for an O-methyl group in MeO-GlcNCys led to a 10-fold increase in K m (40 mM) ( Table 2 ). This increased further to 70 mM for BnO-GlcNCys, which was furnished with a much bulkier O-benzyl aglycone. These observations exemplify how the malate motif of BSH plays a prominent role in its preferential recognition and binding as a SaFosB substrate.
Analysis of the FosA/FosB sequence alignments indicates several amino acid residues that are not found in FosA, but are conserved among the four FosB enzymes that have been shown to recognize BSH as a substrate [21, 37] (Figure 8C) and Swiss Dock were unsuccessful, despite optimization of various parameters such as ligand energy minimization, ligand protonation state and flexibility in ligand and enzyme residues. The inability to successfully model BSH into the FosB structure suggests that a conformational change in FosB may occur during BSH binding, as has been observed previously in structural studies of some glutathione transferases [38] . In the BSH-binding pocket, Lys 35 , Lys 36 and Asn 50 are on the opposite chain of the homodimer to the other conserved residues (Supplementary Figure S6) . Hence any BSH-induced conformational changes that might be propagated across the protein could account for the elements of negative substrate co-operativity between substrates that was observed in the present study. In future, structural studies of BSH-bound FosB would provide more detailed insights into such substrate-binding interactions.
Conclusions
In the present study, mechanistic details of the bacillithiol-S-transferase activity of SaFosB have been established in terms of thiol substrate and metal cofactor preference. SaFosB clearly prefers BSH, rather than cysteine, as its thiol substrate, and probably utilizes both Mn 2 + and Mg 2 + as its physiologically relevant metal cofactors. As the present paper was being submitted, Armstrong and co-workers published a brief communication comparing the effects of Mg 2 + (1 mM) and Ni [37] . Under these conditions, they showed that, whereas Ni 2 + is a better activator of SaFosB than Mg 2 + , the differences are less distinct with the FosB enzymes from the other Gram-positive bacteria. They also commented that Zn 2 + appears to be a potent inhibitor of FosB, but details of these experiments were not reported. In the present study, detailed metal activation studies have shown that Zn 2 + is the most effective for SaFosB activation in vitro. However, when BSH concentrations are greater than Zn 2 + (as they are likely to be in vivo), SaFosB appears to be inactive due to the Zn 2 + being sequestered by BSH.
Considering the virtual absence of free Ni 2 + within the cytosol, it is likely that Mn 2 + and Mg 2 + are the more physiologically relevant metals in vivo. Whether the same metal preferences are reflected among other FosBs [37] remains to be seen and warrants further investigation. The present study demonstrates that the SaFosB-catalysed reaction pathway proceeds through a compulsory ordered mechanism, where fosfomycin binds before BSH. Also, whereas the malate group of BSH is particularly important for substrate recognition, the thiol motif, although essential for catalysis, is not important for ligand binding. These structure-activity relationships may help to facilitate the design of simplified BSH substrate mimics as FosB inhibitors. It will be interesting to see whether similar substrate-binding criteria are mirrored with other BSH-utilizing enzymes, such as the recently discovered DinB class of bacillithiol-S-transferases [39] . In addition, the catalytically inert BSH substrate mimic BOH could potentially prove useful for structural and mechanistic studies of FosB and other BSH-dependent enzymes.
In GSH-utilizing bacteria such as E. coli, GSH plays a sacrificial role in electrophile detoxification, as the glutathione S-conjugates are excreted directly from the cell and into the medium [40] .
Early evidence of a more efficient detoxification pathway has recently been reported for BSH-utilizing bacteria, where the GlcN-Cys amide bond of bacillithiol S-conjugates is hydrolysed by a conjugate amidase allowing the GlcN-Mal motif to be recycled back into BSH biosynthesis [41] . Access to pure BSfosfomycin will now provide an opportunity to establish whether such a mechanism is involved in the BSH-dependent fosfomycindetoxification pathway.
AUTHOR CONTRIBUTION
Alexandra Roberts cloned and purified FosB, and developed and performed all of the kinetic studies and thiol analyses. Sunil Sharma synthesized the AQC, thiol substrates, inhibitor and enzyme products. Andrew Strankman performed the preliminary thiol analysis. Shayla Duran determined the S. aureus fosfomycin MICs. Chris Hamilton, Alexandra Roberts, Sunil Sharma and Mamta Rawat developed the project and interpreted the results and contributed to the writing. 
SUPPLEMENTARY ONLINE
BSH STABILITY
Thiol-stability studies were performed to determine the oxidation rate of BSH and cysteine in Hepes buffers of different pH values ( Figure S1 ). BSH or cysteine (1 mM) was incubated in 25 mM Hepes (pH 7, 7.5 or 8) with 50 mM KCl and 10 mM MgCl 2 . Aliquots were taken at various time points and mixed immediately with 10 mM DTNB [1] in 50 mM sodium phosphate buffer (pH 7.5) with 20 mM KCl and 1 mM MgCl 2 . The absorbance of each reaction was measured at 412 nm to calculate the consumption of thiol using the molar absorption coefficient of 14 150 M − 1 [2] . Previous assays for FosA and FosB used the ratio of RSfosfomycin product to residual RSH substrate in order to quantify their GSH-and cysteine-dependent activities [3] . However, BSH is not stable during derivatization with pH 8.8 borate buffer, preventing its reliable quantification by HPLC. Consequently, RS-fosfomycin standards were made in order to quantify product formation (see below). The RS-fosfomycin products were stable in borate buffer, presumably due to the blocking of the thiol with fosfomycin.
PURIFICATION OF SaFosB
Native SaFosB was expressed heterologously in E. coli BL21 Star TM (DE3) cells in Terrific broth with 25 μM IPTG (isopropyl β-D-thiogalactopyranoside) induction at room temperature. SaFosB was purified using ion-exchange and hydroxyapatite resins, and was demetallated by treating with Chelex and EDTA ( Figure S2 ).
THE EFFECT OF K
+ ON SaFosB ACTIVITY Thiol-consumption (DTNB) assays were used to confirm that K + does not affect the activity of SaFosB. Reaction mixtures contained 100 mM Hepes (pH 7), 50 μM MnCl 2 , 4 mM fosfomycin, 50 μM SaFosB, 1 mM BSH and 0 or 10 mM KCl. Aliquots were taken at various time points and mixed immediately with 10 mM DTNB [1] in 50 mM sodium phosphate buffer (pH 7.5) with 20 mM KCl and 1 mM MgCl 2 . The absorbance of each reaction was measured at 412 nm to calculate the consumption of thiol using the molar absorption coefficient of 14 150 M − 1 [2] . Results are shown in Figure S3 .
BSH INHIBITION OF SaFosB
HPLC-based enzyme assays showed that when [BSH] [fosfomycin], SaFosB activity was inhibited ( Figure S4A ).
Further assays showed that this was not due to the high Mn 2 + concentrations used in the detailed substrate saturation kinetics experiments ( Figure S4B ).
SEQUENCE ANALYSIS OF FosB AND FosA ENZYMES
Clustal Omega [4, 5] was used to align the FosB protein sequences from S. aureus strain ATCC25923 (GenBank ® accession number JF912450), B. anthracis strain Ames (PDB code 4IR0), B. cereus BGSC 6E1 (GenBank ® accession number ZP04314903) (BcFosB) and B. subtilis CU1065 (Uniprot ID 031817) [6] , as well as the FosA sequence from Pseudomonas aeruginosa (PDB code 1LQP) (PaFosA). Sequence identities and similarities were calculated from the Clustal Omega alignments. An alignment image was constructed via ESPript version 2.2 [7] . The secondary structures were predicted by modelling SaFosB on the B. anthracis FosB (BaFosB) structure (PDB code 4IR0) using SWISS-MODEL [8] [9] [10] . Sequence alignments ( Figure S5) show that the FosB sequences are more similar to each other (59-81 % sequence identity) than to FosA (28-34 %). In addition, the sequence identities between the Bacillus FosB proteins (in particular between BaFosB and BcFosB) are higher than with the SaFosB sequence. Strictly conserved residues across all FosA/FosB sequences include the three metal (M 2 + )-binding residues His 7 , His 64 and Glu 110 (PaFosA numbering [11] ).
SURFACE DIAGRAM OF BaFosB CRYSTAL STRUCTURE
The BaFosB crystal structure, with fosfomycin and Zn 2 + bound, was recently deposited in the PDB (PDB code 4IR0). A surface diagram of the active site shows that the metal cofactor (Zn 2 + ) and fosfomycin substrate are buried in the bottom of the binding pocket and the active site is composed of amino acid residues from both chains of the homodimer ( Figure S6 ).
SUBSTRATE SATURATION ASSAYS WITH VARIOUS THIOL SUBSTRATES AT PHYSIOLOGICAL METAL CONCENTRATIONS
As the thiol substrate was shown to affect the metal requirements for FosB in vitro, physiologically relevant Mn 2 + and Mg 2 +
concentrations [12] were used for the comparative kinetic characterization of BSH, cysteine, MeO-GlcNCys and BnOGlcNCys (see Table 2 mixtures contained 100 mM Hepes (pH 7.0), 50 mM fosfomycin, 2 μM FosB and M 2 + (10 mM Mg 2 + , 100 μM Zn 2 + or 10μM Mn 2 + + 10 mM Mg 2 + ) and were incubated at room temperature for 72 h. The assay mixture (100 μl) was diluted with 2 H 2 O (300 μl) and 31 P-NMR data were recorded. BSH (2 mM) was used as a positive control ( Figure S7 ). A reference sample of hydrolysed fosfomycin was prepared by incubating a 100 μl solution of 25 mM fosfomycin in 100 mM HCl overnight at 22
• C before neutralizing with 100 mM NaOH. This was then freeze-dried to give a completely hydrolysed sample of fosfomycin, whose NMR data were in agreement with those previously published [13] .
GENERAL SYNTHETIC EXPERIMENTAL METHODS
Chemical reagents and solvents were purchased from SigmaAldrich, Acros, Fluka, Romil, Avocado and Novabiochem. Deuterated NMR solvents were purchased from Apollo Scientific Limited or Cambridge Isotope Laboratories. HPLC-grade water was used for all reactions. Analytical TLC was performed on Silica Gel 60 F 254 pre-coated aluminium sheets and visualized under UV light or by dipping in an appropriate TLC stain, followed by charring with a heat gun or on a hot plate. TLC stains used included DTNB (for thiols), ninhydrin solution (for amines), 10 % (v/v) ethanolic sulfuric acid (for glycosides) and basic potassium permanganate solution. Automated reverse-phase chromatography was performed on either a Biotage Isolera Four system using Biotage SNAP (12 g, KP-C 18 -HS) cartridges or using a manual solid-phase extraction tube from Isolute C 18 (5 g/25 ml). Optical rotations [α] D were measured using either a PerkinElmer model 241 polarimeter or a Bellingham Stanley ABP220 polarimeter with the specified solvent and concentration, and are quoted in units of 10
IR spectra were recorded on a PerkinElmer Spectrum BX FT-IR system equipped with DurasampR sampler or a PerkinElmer Spectrum One FT-IR spectrometer. NMR spectra were recorded on Bruker 400 MHz spectrometer. The following abbreviations are used: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet; br, broad peak. Low-resolution electrospray ionization mass spectra were recorded on a Shimadzu LC-MS 2010-A instrument using methanol or water as the mobile phase. High-resolution electrospray ionization mass spectra were either conducted at the EPSRC National Mass Spectrometry Service Centre at Swansea University using a Finnigan MAT 900 XLT instrument or at the John Innes Centre, Norwich, using a Thermo Scientific LTQ Orbitrap XL mass spectrometer. Thiol titrations were carried out by the addition of the reaction samples to 2 mM DTNB, in phosphate buffer (pH 7.5), and measuring the absorbance increase at 412 nm on a temperature-controlled PerkinElmer UV Lambda 25 spectrophotometer. Compounds 1 [14] , 4 [15] , 7 [16] and 8 [16] were synthesized as reported previously.
Scheme S1 Synthesis of BOH (compound 3), MeO-GlcNCys (compound 6) and BnO-GlcNCys (compound 9)
SYNTHESIS OF COMPOUND 2
To a solution of compound 1 [16] (200 mg, 0.4 mmol) in anhydrous DMF (dimethylformamide) (5 ml), Boc-NH-Ser-OH (where Boc is t-butoxycarbonyl) (185 mg, 0.9 mmol), PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) (468 mg, 0.9 mmol), HOBt (1-hydroxybenzotriazole) (120 mg, 0.9 mmol) and DIPEA (N,N-di-isopropylethylamine) (116 mg, 0.9 mmol) were added. The reaction mixture was stirred for 12 h under a nitrogen atmosphere at room temperature. Solvent was removed under high vacuum. The crude mixture was dissolved in ethyl acetate (10 ml) and washed with water (2×30 ml). The organic layer was then separated and dried using 
SYNTHESIS OF BOH (3)
In a flame-dried flask, a solution of compound 2 (220 mg, 0.32 mmol), imidazole (110 mg, 1.63 mmol) and triphenylphosphine (26 mg, 0.1 mmol) in anhydrous DCM (dichloromethane) (8 ml) was stirred under nitrogen for 30 min. Tetrakis(triphenylphosphine)palladium (20 mg, 0.018 mmol) was added and the reaction was stirred at room temperature for 16 h. The mixture was filtered through a small column of Dowex-H + resin eluting with methanol to remove the imidazole. The crude mixture containing triphenylphosphine oxide was used for the next step without further purification. The residue was dissolved in anhydrous methanol (4 ml) and freshly prepared 0.5 M sodium methoxide in anhydrous methanol (1.6 ml, 0.8 mmol) was added at 0
• C. The reaction was stirred at 0 • C for 2.5 h and quenched by filtration through Dowex-H + resin. Solvent was evaporated and the crude mixture was treated with a mixture of TFA The fosfomycin substrate and Zn 2 + cofactor (blue sphere) are buried at the bottom of the binding pocket, which would be inaccessible to fosfomycin if BSH were to bind first.
(trifluoroacetic acid), DCM and tetramethylsilane (5 ml, 80:20:1) at 0
• C and stirred for 10 min. The reaction was then allowed to warm to room temperature over 30 min. The solvents were removed under high vacuum to give an oily residue. The product was triturated with ice-cold ether (5 ml) to give a white precipitate, which was dissolved in water (10 ml) and twice washed with cold ether (10 ml). The aqueous layer was then freeze-dried, and purified using a reverse-phase C 18 
SYNTHESIS OF (5)
To a mixture of Boc-NH-Cys(Trt)-OH [where Cys(Trt) is tritylcysteine] (395 mg, 0.85 mmol), compound 4 [16] (120 mg, 0.57 mmol) and PyBOP (440 mg, 0.85 mmol) in anhydrous DMF (2 ml), DIPEA (180 mg, 2.5 mmol) was added. The reaction mixture was stirred for 15 h at room temperature under a nitrogen atmosphere. Solvent was removed under high vacuum. The crude mixture was dissolved in ethyl acetate (10 ml) and washed with water (2× 10 ml). The organic layer was then separated and dried using MgSO 4 , and the solvent was evaporated to give a white solid. This was purified by flash column chromatography (hexane/ethyl acetate 50-90 % gradient) to afford the product 5 as a white solid (155 mg, 44 %).
IR 
SYNTHESIS OF MeO-GlcNCys (6)
A mixture of TFA, DCM and tetramethylsilane (4 ml, 80:20:1) was added to compound 5 (150 mg, 0.24 mmol) at 0 • C and stirred for 10 min. The reaction was allowed to warm to room temperature over 30 min. Solvent was removed under vacuum and the crude product was triturated with ice-cold ether (5 ml) to give a white precipitate, which was dissolved in water (8 ml) and washed with cold ether (2× 10 ml). The aqueous layer was then dried to obtain pure compound 6 as a pale yellow oil (85 mg, quant.).
SYNTHESIS OF BnO-GlcNCys (9)
Resin 7 (0.2 mmol) was pre-swollen by agitation in DMF (20 ml) for 10 min and filtered. A solution of compound 8 [16] (116 mg, 0.43 mmol) in DMF (5 ml) was added, followed by a solution of HOBt (58 mg, 0.43 mmol), PyBOP (223 mg, 0.43 mmol) and 2,6-di-t-butylpyridine (82 mg, 0.43 mmol) in DMF (10 ml) and agitated for 2 h. The resin was washed three times successively with 10 ml portions of DMF (5 min). Fmoc (fluoren-9-ylmethoxycarbonyl) deprotection was carried out by agitation twice in 20 % (v/v) piperidine in DMF (20 ml). The resin was washed twice with DMF (10 ml), then three times with DCM (10 ml). The product was cleaved from the resin by three 3 min treatments with 10 ml portions of TFA, DCM and tetramethylsilane (40:60:3). The combined filtrates were concentrated on a rotary evaporator to give an oily residue, which was triturated with ice-cold ether (5 ml) to obtain a white precipitate. The solid was dissolved in water (8 ml) and washed twice with ice-cold ether (10 ml). The aqueous layer was freezedried and purification using a reverse-phase C 18 
